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Abstract
Alveolar Capillary Dysplasia with Misalignment of Pulmonary Veins (ACDMPV) is a developmental disorder of the lungs,
primarily affecting their vasculature. FOXF1 haploinsufficiency due to heterozygous genomic deletions and point mutations
have been reported in most patients with ACDMPV. The majority of mice with heterozygous loss-of-function of Foxf1 exhibit
neonatal lethality with evidence of pulmonary hemorrhage in some of them. By comparing transcriptomes of human
ACDMPV lungs with control lungs using expression arrays, we found that several genes and pathways involved in lung
development, angiogenesis, and in pulmonary hypertension development, were deregulated. Similar transcriptional
changes were found in lungs of the postnatal day 0.5 Foxf1+/2mice when compared to their wildtype littermate controls; 14
genes, COL15A1, COL18A1, COL6A2, ESM1, FSCN1, GRINA, IGFBP3, IL1B, MALL, NOS3, RASL11B, MATN2, PRKCDBP, and SIRPA,
were found common to both ACDMPV and Foxf1 heterozygous lungs. Our results advance knowledge toward
understanding of the molecular mechanism of ACDMPV, lung development, and its vasculature pathology. These data
may also be useful for understanding etiologies of other lung disorders, e.g. pulmonary hypertension, bronchopulmonary
dysplasia, or cancer.
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Introduction
Alveolar Capillary Dysplasia with Misalignment of Pulmonary
Veins (ACDMPV; MIM# 265380) is a rare developmental
disorder of the lung [1]. ACDMPV was first described by
McMahon [2] and its genetic basis emerged as more patients [3]
and familial cases were reported [4]. The primary diagnostic
features of ACDMPV include misalignment (malposition) of
pulmonary veins, medial thickening of smooth muscles in
pulmonary arteries, hyperplasia of alveolar epithelium, and
drastically decreased number of capillaries and lobular underde-
velopment [5]. Approximately one third of the patients also have
lymphangiectasis. The disease usually presents within a few hours
after birth although late presentations have been reported [6,7].
Treatment, including high pressure oxygen, nitric oxide, extra
corporeal membrane oxygenation (ECMO) [8–11], and more
recently Sildenafil [12], only provide temporary relief as the
disease is uniformly lethal. Most patients die within the first few
weeks of life although some prolonged survivals have been
described [13]. The majority of the patients with ACDMPV also
have extra-pulmonary anomalies, including gastrointestinal, car-
diovascular, and genitourinary systems [14].
We have shown that ACDMPV results from haploinsufficiency
of FOXF1 [15]. To date 42 point mutations and 18 genomic
deletions involving FOXF1 or its upstream regulatory region have
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been identified in patients with ACDMPV [15–17]. Interestingly,
our recent work has indicated that FOXF1 is incompletely
paternally imprinted in human lungs [17,18]. Foxf1+/2 mice
exhibit neonatal mortality similar to human infants with
ACDMPV and die due to defects in vasculogenesis and
alveolarization [19]. They also demonstrate other foregut malfor-
mations such as narrowing of the esophagus and trachea,
esophageal atresia and trachea-esophageal fistula [20]. Unlike in
humans, Foxf1 was not found to be imprinted in mice (data not
shown).
To better understand the molecular bases of ACDMPV and to
identify major genes and pathways involved in lung development,
we performed comparative analyses of lung transcriptomes in
patients with ACDMPV and in Foxf1+/2 mice using Human Ref-8




Patients with histopathologically-verified ACDMPV were
recruited after signing consent for the study, Institutional Review
Board (IRB) protocol # H-8712 ‘‘Molecular genetics of Alveolar
capillary dysplasia with misalignment of pulmonary veins
(ACDMPV)’’ approved by the IRB for Baylor College of Medicine
(BCM) and Affiliated Hospitals. All mouse experiments were
carried out under the approval of the Institutional Animal Care
and Use Committee (IACUC) at BCM. Mice were housed in the
Transgenic Mouse Facility (barrier level 3) under the care of the
Center for Comparative Medicine (CCM), which is accredited by
the Association for Assessment and Accreditation of Laboratory
Animal Care (AAALAC).
Patients
The clinical descriptions are shown in Table 1. Patients 3 and 6
were of Hispanic ethnicity and the remainder were Caucasians.
Patients 2–8 had sporadic ACDMPV and patient 1 represents a
familial case with neither point mutation in FOXF1 nor deletion in
the 16q24.1 region identified. Patients 3 & 4 and 2, 5, & 6 were
reported by Stankiewicz et al (2009) (pts D4 and M4) and by Sen
et al (2013) (pts 15, 1, and 2), respectively. Patients 2 and 5 had
missense mutations, patient 4 had a no stop mutation, patient 6
had a nonsense mutation and patient 3 had an approximately 1
Mb deletion involving FOXF1 as well its upstream regulatory
region. Patients 2–6 had associated anomalies of the gastrointes-
tinal system. Butterfly vertebrae were identified in the patients 3
and 6. In patient 1, autopsy was limited to heart and lung. No
clinical or molecular information about patients 7 and 8 was
available.
Animals
Foxf1+/2 mice with one Foxf1 allele disrupted by deletion of the
forkhead binding domain were generated (Figure S1) and
maintained on a mixed 129-C57BL6/J background. The mid-
day of vaginal plug identification was considered as embryonic day
0.5 and the mid-day when pups were born was considered as
postnatal day (P) 0.5.
RNA isolation
Total RNA was isolated from approximately 10 mg frozen lung
samples from patients and normal control humans using TRIzol
(Invitrogen). Controls C1-C4 are age-matched lung samples from
individuals that had no lung problems and died of other reasons.
Control samples C1-C3 are from females and control sample C4 is
a male sample. Control sample C5 is a commercially available
human total lung RNA (Life Technologies Cat. No# AM7968).
The tissue was homogenized in microfuge tubes with a hand held
homogenizer in the presence of 200 ml of TRIzol. The aqueous
phase was collected after spinning at 10,000 rpm for 5 min. This
step was repeated and the pooled aqueous phase was loaded onto
an RNeasy column (Qiagen). RNA was eluted from the columns
following the manufacturer’s instruction. The RNA was quantified
using Nanodrop and its quality was assessed on a BioRad
Bioanalyzer. In spite of the differences in their process of collection
and preservation, the RNA isolated from the lung tissues of
patients with ACDMPV were of good quality.
Mouse RNA was extracted from frozen whole lungs of P0.5
Foxf1+/2 mice and their wildtype littermate controls. Whole lungs
were homogenized using TissueLyser LT (Qiagen) in QIAzol lysis
reagent (Qiagen) according to manufacturer’s instructions. Total
RNA was isolated from lung homogenates using the miRNeasy
mini kit (Qiagen). RNAs were tested for quality on the Agilent
2100 bioanalyzer and quantified on the Nanodrop Spectropho-
tometer by the Genomic and RNA Profiling Core (GARP) facility
at BCM.
Microarray analysis
500 ng of total human RNA was converted into cDNA and
then cRNA following the manufacturer’s instructions. The cRNA
was biotinylated and hybridized to the Human Ref8.V3 micro-
array (Illumina) contains probes representing ,22,000 curated
genes and ESTs conjugated with streptavidin-Cy3. Quality
standards for hybridization, labeling, staining, background signal,
and basal level of housekeeping gene expression for each chip were
verified. The scanned images of the chip were analyzed using
GenomeStudio software (Illumina). Gene expression analyses of
RNA from patients’ lungs (n = 8) was compared to those from the
control lungs (n = 5).
Transcriptomes of six Foxf1+/2 and six wildtype littermate
samples were assessed in two separate microarray experiments
using MouseWG-6 v2.0 Expression BeadChip kit (Illumina)
containing probes for over 45,200 transcripts. 500 ng of total
RNA was labeled using Illumina TotalPrep RNA Amplification
Kit (Ambion) and hybridized as per manufacturer’s instructions.
The array data were analyzed using the lumi bioconductor
package [21], normalized by robust spline normalization (RST),
and transformed using variance stabilization transformation (VST)
[22]. ComBAT batch correction [23] was applied to correct for
differences in expression values between the two separate
microarray experiments. Two-sample t-test was applied to
determine differentially expressed genes between Foxf1+/2 and
wild type lung groups. Differential expression p-values were
adjusted for false discovery rates (FDR). Fold changes were
calculated using reverse VST.
Database for Annotation, Visualization, and Integrated Discov-
ery (DAVID), Ingenuity pathway analysis (IPA), and Gene set
enrichment analysis (GSEA) softwares were used for gene
ontology, pathway, and network analyses.
The ACDMPV and Foxf1+/2 lung microarray data sets can be
accessed through the NCBI Gene Expression Omnibus (GEO)
(http://www.ncbi.nih.gov/geo/) under accession numbers
GSE54780 and GSE54128, respectively.
qRT-PCR
Confirmation of the differential gene expression was done by
qRT-PCR using an ABI 7900HT Fast real time PCR System.
Universal probe library and Fast start probe master mix from
Expression Changes in ACDMPV Foxf1+/2 Lungs
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Roche Applied Science was used following manufacturer’s
instructions.
For the mouse microarray analysis validation, RNA was reverse
transcribed to cDNA using the SuperScript III First-Strand
Synthesis System (Life Technologies) and amplified using the
Power SYBR Green PCR Master Mix (Life Technologies).
Primers used for qRT-PCR validation of the mouse microarray
are listed in table S5.
Immunohistochemistry
Antibody against COL1A1 was obtained from Sigma-Aldrich.
The respective dilutions of antibodies and other experimental
conditions used were following manufacturer’s instructions.
Results
ACDMPV lung gene expression analysis
Statistical analysis revealed 337 genes deregulated in ACDMPV
lungs compared to control lungs (adjusted p-value ,0.05, fold-
change approximately ./= 2 or ,/= 22), of which 205
(60.83%) were down-regulated and 132 (39.17%) were up-
regulated (Figure 1A, Table S1). DAVID analysis revealed gene
ontologies (GO) related to inflammation and immune responses,
vasculature development, cell adhesion and chemotaxis associated
with the deregulated genes (Figure 1B). The microarray data were
validated using qRT-PCR for eight differentially expressed genes:
IL8, SPP1, IGFBP3, COL1A1, SOD2, GLI2, ANGPTL4, and HES4
(data not shown). Further, differences in protein quantity were
assessed by immunohistochemistry (IHC) using antibodies against
a significantly differentially expressed (COL1A1) product
(Figure 1C). The amount of COL1A1 was significantly higher in
the patient samples as compared to the control lung.
GSEA and DAVID analyses showed enrichment of pathways
related to signaling in the immune system, hemostasis, cell surface
interactions at the vascular wall, and the lysosome (Table S2).
Further analyses by GSEA allowed determining gene sets associated
with chemical and genetic perturbations enriched in the 337 genes
deregulated in the ACDMPV lungs (Table S3). Genes up-regulated
in vascular smooth muscle cells by MAPK8, and genes up-regulated
in the Kras2LA lung cancer mouse model, are enriched in the list of
down-regulated genes. Genes up-regulated by E-cadherin, and
genes down-regulated in the Kras2LA lung cancer mouse model are
enriched in the list of up-regulated genes. IPA pathway analysis was
used to build networks and demonstrate interactions among the
deregulated genes (Figure 2). Top networks involve cellular
movement, cellular proliferation, inflammatory response, cardio-
vascular disease, hematological system development, and carbohy-
drate and lipid metabolism.
Foxf1+/2 mouse lung gene expression analysis
Statistical analysis showed 789 deregulated genes in Foxf1+/2
lungs compared to control lungs (FDR, 0.05, fold-change ./=
1.5 and,/= 21.5) (Figure 3A). 394 genes of them (49.93%) were
down-regulated and 395 (50.06%) were up-regulated (Table S4).
GSEA and DAVID analyses revealed GO terms related to
response to cytokine stimulus, cell division, blood circulation,
regulation of cell proliferation and cell adhesion associated with
deregulated genes (Figure 3B).
The microarray data were confirmed using qRT-PCR for five
differentially expressed genes: Dll4, Hgf, Sema3C, Cma1, and Ren1
(Figure 3C). Canonical pathways affected include genes involved
in focal adhesion, homeostasis, p53 signaling, as well as in Vegf,
Endothelin, and Notch signaling (Table S6). Additional GSEA
analysis identified genes down-regulated by E-cadherin and genes
up-regulated in vascular smooth muscle cells by MAPK8 to be
enriched in the list of down-regulated genes. Genes regulated by
hypoxia were found to be enriched in the list of up-regulated genes
(Table S7). Network analysis by IPA identified interactions
amongst genes involved in cellular movement, inflammatory
response, and hematological and cardiovascular system develop-
ment (Figure 4).
Gene expression alterations common to both ACDMPV
and Foxf1+/2 lung transcriptomes
To identify genes regulated by both FOXF1 and Foxf1 in human
and mouse lungs, respectively, we compared genes with similarly
altered expression in both ACDMPV patients and P0.5 Foxf1+/2
pups and identified fourteen intersecting genes (Figure 5; Table
S8). Ten genes: COL15A1, COL18A1, COL6A2, FSCN1, IGFBP3,
MALL, MATN2, NOS3, PRKCDBP, and RASL11B upregulated in
ACDMPV patients were also upregulated in Foxf1+/2 pups. Four
Table 1. ACDMPV patient sample information.
Patient Gender Ethnicity Inheritance
Life span
(days) FOXF1 molecular defect Associated anomalies
P1 M Caucasian Familial 48 None Limited autopsy
P2 M Caucasian Sporadic 7 Missense mutation (c.286G.
A;p.V96M)
Malrotation of the intestine, atrial septal
defect, thick distended bladder with
muscular hypertrophy, mild bilateral
hydroureter and hydronephrosis
P3 F Hispanic Sporadic 21 Deletion (chr16: 84,402,571–
85,435,712) (hg18)
Imperforate anus, suspected malrotation of
the intestine, bicornuate uterus, multiple
butterfly vertebrae
P4 M Caucasian Sporadic 46 No stop mutation (c.1138T.
C;*380Rext*73)
Malrotation of the colon, Meckel’s
diverticulum
P5 M Caucasian Sporadic 28 Missense mutation (c.145C.
T;p.P49S)
Incomplete rotation of bowel, right colon
unfixed
P6 F Hispanic Sporadic 18 Nonsense mutation (c.89C.
A;p.S30*
Malrotation of the intestine, imperforate
anus, butterfly vertebrae, ventricular septal
defect
No clinical or genetic information is available for patients 7 and 8.
doi:10.1371/journal.pone.0094390.t001
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genes: ESM1, GRINA, IL1B, and SIRPA were downregulated in
ACDMPV patients and also Foxf1+/2 pups. However, five genes
ORM1, FGG, KLF4, IGFBP5, and GAMT were found to be
differentially altered in the human vs mouse microarray datasets.
Discussion
To date, we have recruited greater than 100 families with
children affected with ACDMPV. This is the largest collection of
ACDMPV samples worldwide. To identify transcriptional changes
in the neonate ACDMPV lungs, we compared the whole genome
expression in the lungs of eight patients with ACDMPV with
transcriptional changes in P0.5 Foxf1+/2 mouse lungs, and
appropriate control lungs. This approach enabled us to identify
gene ontologies and pathways associated with ACDMPV and gain
a better understanding of the disease.
The Foxf1+/2 mouse lungs showed down-regulation of Notch
signaling genes Dll4 and Notch1 and slightly lower but significant
(fold change: 21.46) down-regulation of the Notch target gene
Hey1 (data not shown). Notch signaling has been reported to be
affected in Foxf1+/2 lungs [24]. Genes involved in pulmonary
vasculature development, Sema3c and lung branching morphogen-
esis, Hgf and Lama1, were also down-regulated. Sema3c, a
semaphorin gene expressed in the lung endothelium, interacts
with neuropillin-1 during vasculature development; loss of
semaphorin-neuropilin-1 signaling showed lung pathology remi-
niscent of ACDMPV [25]. Sema3c was down-regulated in our
study and Foxf1 was down-regulated in lungs of Nrp1Sema- mice,
suggesting a possible interaction between Foxf1 and Sema3C in
murine lung pathology. These transcriptional changes potentially
lead to underdeveloped lungs causing respiratory distress at birth.
Transcriptional changes found in Foxf1+/2 lungs, potentially
resulting from the respiratory distress, include deregulation of
pathways associated with hypoxia-induced vascular remodeling.
There is increased expression of a-smooth muscle actin Acta2,
indicating greater muscularization of pulmonary vessels and
possible pulmonary hypertension. Greater expression of Acta2
could also be due to endothelium-to-mesenchyme transition that is
found to accompany vascular remodeling in pulmonary hyper-
tension [26]. Additionally, members of the Endothelin-1 signaling
pathway were deregulated. Endothelin-1 (ET-1) is a potent
vasoconstrictor regulating vascular tone and is implicated in
pulmonary hypertension. Edn1 over-expression in mice leads to
Figure 1. ACDMPV lung microarray analysis: heat map, clustering, DAVID analysis, and IHC validation. (A) Heat map for genes
differentially expressed (adjusted p-value ,0.05, fold change approximately ./ = 2 or ,/ = 2 2) between ACDMPV lungs (n = 8) and control lungs
(n = 5); Decreased gene expression is shown in green and increased gene expression is shown in red. (B) Top significant gene ontology (biological
processes) terms associated with deregulated genes identified by DAVID analysis. (C) IHC validation for COL1A1; Representative slides from two
patients’ and one control sample at 206magnification. A commercial control lung sample C5 clustered with the age-matched control lung samples
C1-4. A lung sample from a patient who died from a different congenital diffuse lung developmental disorder was also included in the analysis. The
deregulated genes in this sample clustered differently than those in ACDMPV lung samples (data not shown), confirming the validity of our approach.
doi:10.1371/journal.pone.0094390.g001
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development of systemic hypertension with altered vascular
reactivity [27].
Fibronectin and several members of the collagen gene family
are also found to be up-regulated, likely leading to increased
production of extracellular matrix (ECM) proteins. Accumulation
of ECM proteins such as collagen, elastin, and fibronectin leads to
thickening of pulmonary blood vessels, likely contributing to
pulmonary hypertension. Interestingly, endothelin induced colla-
gen remodeling has been reported in a mouse model of pulmonary
hypertension [28], indicating that the increased endothelin-1
signaling in Foxf1+/2 lungs may be causing an increase in collagen
production. Integrins involved in cell surface interactions at the
vascular wall were also found to be down-regulated. Similar
transcriptional changes have been observed to be associated with
matrix and vasculature remodeling in TGF-a induced pulmonary
fibrosis [29]. Foxf1 was shown to play an essential role in
mesenchymal migration by transcriptionally regulating integrin-
b3 (Itgb3) [30]. Integrin-ECM interactions also contribute to
vascular remodeling. Altered integrin-ECM interactions have been
documented in chronic hypoxia and monocrotaline-induced
pulmonary hypertension [31].
Mast cell chymase and tryptase genes (Mcpt4, Mcpt6, Cma1, and
Cpa3) are highly up-regulated i n Foxf1+/2 lungs, showing evidence
of pulmonary mastocytosis. Pulmonary mastocytosis and enhanced
lung inflammation in Foxf1+/2 mice after chemically induced or
allergen-mediated lung injury was reported [32]. These inflam-
matory molecules could contribute to the vascular remodeling
through their effects on vascular cell wall permeability, matrix
protein production, and by inducing recruitment of mesenchymal
precursor cells [33]. Similar accumulation of mast cell mediators
was found in lungs of Fgfr3/4 mutant mice that exhibit
Bronchopulmonary Dysplasia (BPD) like pathology and in lungs
Figure 2. Networks involving deregulated genes in ACDMPV lungs identified using IPA; down-regulated genes are shown in green
and up-regulated genes are shown in red. Deregulated genes involved in (A) Cellular movement, immune cell trafficking, inflammatory
response; (B) Cellular development, cellular growth and proliferation, tumor morphology; (C) Cellular development, hematological system
development and function, immune cell trafficking; (D) Cardiovascular disease, inflammatory response and cellular movement; (E) Carbohydrate
metabolism, lipid metabolism and molecular transport.
doi:10.1371/journal.pone.0094390.g002
Figure 3. Foxf1+/2 mouse lung microarray analysis: heat map, clustering, DAVID analysis, and qRT-PCR validation. (A) Heat map for
genes differentially expressed (fdr ,0.05, fold change ./ = 2 or ,/ = 2 2) between Foxf1+/2 lungs (n = 6) and littermate control lungs (n = 6);
Decreased gene expression is shown in green and increased gene expression is shown in red; Foxf1+/2 lung samples and wildtype lung samples
cluster as two separate groups. (B) Top significant gene ontology (biological processes) terms associated with deregulated genes from DAVID
analysis. (C) qRT-PCR validation for down-regulated genes (Sema3C, Dll4, and Hgf) and up-regulated genes (Cma1 and Ren1); n = 6 for each group; * =
p value ,0.05; ** = p value ,0.001.
doi:10.1371/journal.pone.0094390.g003
Expression Changes in ACDMPV Foxf1+/2 Lungs
PLOS ONE | www.plosone.org 6 April 2014 | Volume 9 | Issue 4 | e94390
of children with BPD [34], suggesting that pulmonary mastocytosis
could be a common feature found in diffuse lung developmental
conditions. Ren1 which along with Cma1 and Cpa3 is a component
of the blood pressure regulating renin angiotensin system is also
up-regulated.
Other transcriptional changes include up-regulation of Mki67,
Ccnd1, and Foxm1, showing an increase in proliferation in the lung.
Foxf1 has been reported to be down-regulated in mice with
endothelial cell-specific deletion of Foxm1 [35], indicating a
reciprocal feedback loop between Foxf1 and Foxm1. Finally, up-
regulation of Hif3a and Nos3 is also observed, suggesting a
compensatory mechanism to counteract the effects of hypoxia-
induced pulmonary hypertension.
Microarray analysis of ACDMPV human lung transcriptomes
primarily identified deregulation of genes involved in inflamma-
tion and cell surface interactions at the vascular wall. Members of
the collagen gene family are highly up-regulated similar to the up-
regulation seen in Foxf1+/2 lungs, potentially leading to increased
ECM collagen production, causing thickening of pulmonary blood
vessels, and resulting in pulmonary hypertension, a typical feature
found in neonates with ACDMPV.
IHC for COL1A1 confirmed the increased protein levels of
COL1A1 in ACDMPV patient lungs (Figure 1C). Structural
changes in ACDMPV lungs that could be attributed to hypoxia-
induced vascular remodeling include medial thickening of smooth
muscles in pulmonary arteries. Transcriptional changes which
could be described as compensatory mechanisms to counteract the
pulmonary hypertension include down-regulation of genes in-
volved in TREM1 signaling (TREM1, TLR4, IL1B, and ITGAX)
and up-regulation of NOS3. Pulmonary inflammatory responses
play an important role in hypoxia-induced vascular remodeling
[33] and down-regulation of TREM1 signaling could be a
Figure 4. Networks involving deregulated genes in Foxf1+/2 lungs identified using IPA. Deregulated genes involved in (A) Inflammatory
response, cellular movement, cardiovascular disease; (B) Cell-to-cell signaling and interaction, cellular movement, hematological system development
and function; (C) Embryonic development, organ development; (D) Cardiovascular system development and function, organ development, cellular
movement; down-regulated genes are shown in green and up-regulated gens are shown in red.
doi:10.1371/journal.pone.0094390.g004
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compensatory response to attenuate pulmonary inflammatory
responses. Tlr-4 deficient mice were shown to be resistant to
chronic hypoxia-induced pulmonary hypertension by attenuating
the pulmonary vascular inflammatory response to hypoxia [36].
Up-regulation of NOS3 also could be a compensatory response to
counteract the hypertension.
Other affected pathways include signaling related to the lysosome
function, carbohydrate metabolism, cell cycle, and axon guidance
which are also deregulated in Foxf1+/2 lungs. Interestingly, we
found targets of E-cadherin enriched in the deregulated genes.
Recently, E-cadherin has been shown to be a target of FOXF1,
which in turn has been shown to be a target of p53, regulating
cancer cell migration and invasiveness [37]. Additionally, FOXF1
expression has been shown to be changed in numerous human
malignancies [38–45].
Comparison of the deregulated genes in both experiments
enabled identification of 14 genes, COL15A1, COL18A1, COL6A2,
ESM1, FSCN1, GRINA, IGFBP3, IL1B, MALL, NOS3, RASL11B,
MATN2, PRKCDBP, and SIRPA, similarly altered in both
ACDMPV and Foxf1 heterozygous lung transcriptomes. ESM1 is
mainly expressed in endothelial cells and its expression is
upregulated by cytokines like TNFa and IL-1b suggesting that it
plays a role in endothelium-dependent pathological disorders [46].
ESM1 as well as IL1B are downregulated in both the microarray
datasets. ESM1 has also been computationally predicted to have a
FOX: ETS binding motif in its vicinity suggesting that it could be
a direct target of FOXF1 in endothelial cells [47]. Another
common downregulated gene in both datasets, SIRPA has been
shown to interact with surfactant proteins A & D in the absence of
inflammation to suppress alveolar macrophage phagocytosis [48].
Whereas there is greater variation for Sirpa in the mouse data, the
average fold change difference for this gene correlates with the
human data.
In aggregate, we present the results of genome-wide analyses of
transcriptional changes in lungs from patients with ACDMPV due
to point mutations or genomic deletions in FOXF1 and in mice
heterozygous for Foxf1 loss. The transcriptional changes should
help better define the molecular mechanisms involved in the
pathogenesis of ACDMPV and may also be a valuable source for
future research on lung vasculature development and pulmonary
disease conditions such as pulmonary hypertension, bronchopul-
monary dysplasia, and lung cancer.
Supporting Information
Figure S1 Generation of the Foxf1+/2 mouse line. Single
allele deletion of the Foxf1 gene was achieved by breeding of Foxf1-
floxed heterozygous females with EIIa-Cre male mice. Foxf1-floxed
allele possesses two LoxP sites (white arrowhead) and one Frt site
that surround exon 1, encoding the Forkhead DNA-binding
domain of the Foxf1 protein. Cre-mediated recombination occurs
in a wide range of tissues, including the germ cells that transmit
Foxf1-null allele to offspring. Exon 1 and part of the promoter of
Foxf1 are deleted. The GRCm38/mm10 coordinates of the
deleted region are chr8:121,083,499-121,085,436 (1938 bp). Fendrr
is a long non coding RNA gene located upstream to Foxf1, and
negatively regulates it. Primer sequences used to genotype mice




Table S1 ACDMPV lung microarray analysis: List of
deregulated genes (adjusted p value,0.05, fold change.
/= 2 or ,/= - 2).
(XLSX)
Table S2 Pathways enriched in ACDMPV lung tran-
scriptomes: GSEA and DAVID analyses (p-value ,0.05).
(XLSX)
Table S3 Chemical and genetic perturbation gene sets
enriched in ACDMPV lungs: GSEA analysis (fdr ,0.05).
(XLSX)
Table S4 Foxf1+/2mouse lung microarray analysis: List
of deregulated genes (fdr,0.05, fold change. /= 1.5 or
,/= 2 1.5).
(XLSX)
Figure 5. Deregulated genes common to both ACDMPV lungs
and P0.5 Foxf1+/2 lungs. (A) Heat map comparing expression of 14
overlapping genes in ACDMPV lung samples and control lung samples;
(B) Heat map comparing expression of 14 overlapping genes in Foxf1+/2
lung samples and control lung samples.
doi:10.1371/journal.pone.0094390.g005
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Table S5 List of primer sequences used for qRT-PCR
validation using SYBR.
(XLSX)
Table S6 Pathways enriched in Foxf1+/2 lung transcrip-
tomes: GSEA and DAVID analyses (p-value ,0.05).
(XLSX)
Table S7 Chemical and genetic perturbation gene sets
enriched in Foxf1+/2 lungs: GSEA analysis (fdr ,0.05).
(XLSX)
Table S8 GO terms associated with genes similarly
altered in both ACDMPV lungs and Foxf1+/2 lungs.
(XLSX)
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